BioMotiv Expands Partnership with Biogen, Raises $10 Million

September 6, 2016

BioMotiv, a Cleveland therapeutic development company, and Biogen have expanded their existing strategic partnership to include ophthalmology medicines. The expansion includes an additional $10 million Biogen investment into BioMotiv, bringing BioMotiv’s total capitalization to $145 million.